Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044433 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL1278398 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL317355 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Palmitate SCHEMBL1133116 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL126208 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Palmitate SCHEMBL22578002 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL1173030 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Palmitate SCHEMBL7743 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL43528 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Myristate SCHEMBL2552125 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115484824-B | Compound combination having excellent herbicidal activity | 拜耳公司 | 2025-04-04 | — | — | CN | claimed |
| CN-117447326-B | Method for catalyzing carbonylation esterification reaction by cobalt compound activated by synthesis gas | 中国科学院兰州化学物理研究所 | 2024-08-27 | — | — | CN | claimed |
| CN-118284600-A | Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof | 曙方(上海)医药科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-115397242-B | Compound combination with excellent herbicidal activity | 拜耳公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117447326-A | Method for catalyzing carbonylation esterification reaction by cobalt compound activated by synthesis gas | 中国科学院兰州化学物理研究所 | 2024-01-26 | — | — | CN | claimed |
| WO-2024003737-A1 | PROCESS AND INTERMEDIATES USEFUL FOR PREPARING NIRMATRELVIR | PFIZER INC. (US) | 2024-01-04 | — | — | WO | claimed |
| CN-117285413-A | Synthesis method of terbutaline key intermediate 3, 5-dihydroxyacetophenone | 重庆恩联生物科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2023083293-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ELIGLUSTAT AND CRYSTAL FORM THEREOF | 曙方(上海)医药科技有限公司 | 2023-05-19 | — | — | WO | claimed |
| CN-116120274-A | Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof | 曙方(上海)医药科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-112645982-B | Preparation and purification method of key intermediate of Rudexiluwei | 苏州正济药业有限公司 | 2023-04-07 | — | — | CN | claimed |
| EP-2734504-A1 | POLYMORPHIC FORMS OF COMPOUNDS AS PROLYL HYDROXYLASE INHIBITOR, AND USES THEREOF | Beijing Betta Pharmaceuticals Co., Ltd (CN) | 2014-05-28 | — | — | EP | claimed |
| US-8563530-B2 | Purine nucleoside phosphoramidate | Gilead Pharmassel LLC (US) | 2013-10-22 | — | — | US | claimed |
| EP-2552933-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2013013609-A1 | POLYMORPHIC FORMS OF COMPOUNDS AS PROLYL HYDROXYLASE INHIBITOR, AND USES THEREOF | ZHEJIANG BETA PHARMA INCORPORATION (CN) | 2013-01-31 | — | — | WO | claimed |
| US-20110257121-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PHARMASSET, INC. (US) | 2011-10-20 | — | — | US | claimed |
| WO-2011123672-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| US-7833957-B2 | Removing solution | DAIKIN INDUSTRIES, LTD. (JP) | 2010-11-16 | — | — | US | claimed |
| US-20060138399-A1 | Removing solution | DAIKIN INDUSTRIES, LTD. (JP) | 2006-06-29 | — | — | US | claimed |
| CN-1678961-A | Removing solution | DAIKIN IND LTD (JP) | 2005-10-05 | — | — | CN | claimed |
| EP-1536291-A1 | REMOVING SOLUTION | Daikin Industries, Ltd. (JP) | 2005-06-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257121-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PNP, NUDT1, TYMP | LMNA 3074/4885MAPT 2853/4885MAPK1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.